Vytrus Biotech S.A. (MC:VYT) — Market Cap & Net Worth
Market Cap & Net Worth: Vytrus Biotech S.A. (VYT)
Vytrus Biotech S.A. (MC:VYT) has a market capitalization of $135.30 Million (€115.73 Million) as of June 22, 2026. Listed on the MC stock exchange, this Spain-based company holds position #18110 globally and #117 in its home market, demonstrating a 10.64% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Vytrus Biotech S.A.'s stock price €18.20 by its total outstanding shares 7516458 (7.52 Million). Review Vytrus Biotech S.A. total liabilities to assess the company's total debt and financial obligations.
Vytrus Biotech S.A. Market Cap History: 2022 to 2026
Vytrus Biotech S.A.'s market capitalization history from 2022 to 2026. Data shows growth from $29.88 Million to $159.93 Million (64.81% CAGR).
Vytrus Biotech S.A. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Vytrus Biotech S.A.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
8.97x
Vytrus Biotech S.A.'s market cap is 8.97 times its annual revenue
Latest Price to Earnings (P/E) Ratio
25.94x
Vytrus Biotech S.A.'s market cap is 25.94 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $29.88 Million | $3.68 Million | $605.26K | 8.11x | 49.36x |
| 2023 | $28.82 Million | $3.74 Million | $544.94K | 7.71x | 52.89x |
| 2024 | $18.98 Million | $5.04 Million | $1.02 Million | 3.76x | 18.59x |
| 2025 | $75.13 Million | $8.37 Million | $2.90 Million | 8.97x | 25.94x |
Competitor Companies of VYT by Market Capitalization
Companies near Vytrus Biotech S.A. in the global market cap rankings as of June 22, 2026.
Key companies related to Vytrus Biotech S.A. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #571 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.70 |
| #571 | Argen-X | BR:ARGX | $47.14 Billion | €773.80 |
Vytrus Biotech S.A. Historical Marketcap From 2022 to 2026
Between 2022 and today, Vytrus Biotech S.A.'s market cap moved from $29.88 Million to $ 159.93 Million, with a yearly change of 64.81%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €159.93 Million | +112.87% |
| 2025 | €75.13 Million | +295.83% |
| 2024 | €18.98 Million | -34.15% |
| 2023 | €28.82 Million | -3.53% |
| 2022 | €29.88 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 21st, 2026 the market cap of Vytrus Biotech S.A. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $135.30 Million USD |
| MoneyControl | $135.30 Million USD |
| MarketWatch | $135.30 Million USD |
| marketcap.company | $135.30 Million USD |
| Reuters | $135.30 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Vytrus Biotech S.A.
Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. It offers Clarivine that activates skin's regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Lon… Read more